Sagimet Biosciences Inc. SGMT

Rank #2195 · Nasdaq · $0.3B market cap

Audited by KPMG LLP, no going-concern flag in the latest filing.

Score

29.7

P/E

-6.7

P/B

3.34

ROE

-50.0%

Op. Margin

–%

Debt Ratio

76%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -6.7x, P/B 3.34x. Ranks in the top 71% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -50.0%. Ranks in the top 88% of the universe.

Safety ★★★☆☆

Good

Debt ratio 76%. Ranks in the top 32% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2023	$0.0B	$-0.0B	$-0.0B	$-0.2B	-1552.8	-3
2024	$0.0B	$-0.0B	$-0.0B	$-0.2B	-1537.0	-152
2025	–	$-0.1B	$-0.0B	$0.1B	–	76